Table 1. Background of 47 metastatic clear cell RCCs

	1st line	2nd line (n=41)		3rd line (n=20)	
	IFN-alpha	IFN-alpha + sorafenib		Axitinib	
	CR/PR/SD>24 w (n=6)	CR/PR/SD>24 w (n=19)	SD<24w/PD (n=22)	CR/PR/SD>24 w (n=9)	SD<24w/PD (n=11)
Sex (Male / Female)	32 / 15				
Years (median)	39-78 (65)				
ECOG PS* (0 / 1 / 2)	29 / 14 / 4	6 / 0 / 0	13 / 6 / 0	10 / 8 / 4	4 / 5 / 0	2 / 8 / 1
MSKCC* (Fav / Int / Poor)	24 / 15 / 8	6 / 0 / 0	9 / 7 / 0	9 / 8 / 8	2 / 7 / 0	1 / 8 / 2
Duration of IFN-alpha* (mean : months)		7-46 (15.9)				
Duration of pre-IFN-alpha* (mean : months)			1-31 (7.4)			
Duration of IFN-alpha + sorafenib (mean : months)			1-81 (19.7)			
Duration of axitinib (mean : months)					1-37 (11.6)	
Metastatic lesions* (numbers)						
PUL	46	6	18	22	9	11
PLE	6	1	2	3	2	2
HEP	7	0	3	4	2	2
OSS*	11	0	6	5	3	3
LYM	12	0	6	6	3	4
Others	3	0	0	3	0	2

ECOG PS* : Eastern Cooperative Oncology Group (ECOG) performance status

MSKCC* : Memorial Sloen-Kettering Cancer Center, Fav; Favorable, Int; Intermediated, Poor; Poor risk

Duration of IFN-alpha* : Duration of IFN-alpha monotherapy

Duration of pre-IFN-alpha* : Duration of IFN-alpha monotherapy prior toIFN-alpha plus sorafenib

Metastatic lesions* ; PUL; Lung, PLE; Pleura, HEP; Liver, OSS; Bone, LYM; lymph node

OSS* : Treatment option with Radiation plus Bisphosphonate or Denosmab